The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Selection of Hypoglycemic Agents in Type 2 Diabetes

Individualized antidiabetic therapy approach based on patient profile.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Selection of Hypoglycemic Agents in Type 2 Diabetes?

Drug selection in type 2 diabetes is no longer based solely on lowering HbA1c, but on an individualized approach based on cardiovascular and renal protection, weight management, and risk of hypoglycemia.

ASCVD (atherosclerotic cardiovascular disease) or high risk: addition of GLP-1 RA or SGLT2i (independent of metformin). CKD (GFR <60 or albuminuria): addition of SGLT2i. Heart failure: addition of SGLT2i. These should be initiated independent of HbA1c level for these indications.

GLP-1 RAs (semaglutide, liraglutide, dulaglutide) have strong effects on both HbA1c and weight. Tirzepatide (GIP/GLP-1 dual agonist) is a next-generation agent providing the highest reduction in HbA1c and weight.

Symptoms

Failure to reach target HbA1c
Weight gain (with insulin or sulfonylurea)
Hypoglycemia episodes
Cardiovascular event
Worsening kidney function

Risk Factors

History of cardiovascular disease
Chronic kidney disease
Heart failure
Obesity
Susceptibility to hypoglycemia (elderly, renal failure)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • If HbA1c is not at target, for treatment adjustment
  • If recurrent hypoglycemia episodes are occurring
  • If a cardiovascular event has occurred (treatment optimization)
  • If there is deterioration in kidney function

Treatment Methods

01
Metformin (first-line — if no contraindication)
02
GLP-1 RA (semaglutide, liraglutide, tirzepatide — preferred in ASCVD/CKD/obesity)
03
SGLT2i (empagliflozin, dapagliflozin — preferred in HF/CKD)
04
DPP-4i (sitagliptin — neutral for hypoglycemia and weight)
05
Basal insulin (when oral agents fail to achieve target)
06
Tirzepatide (GIP/GLP-1 dual agonist — strongest HbA1c and weight effect)

Which Department to Visit?

You can visit our Endokrinoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Endokrinoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Thyroid Nodule Evaluation

Endokrinoloji

Thyroid nodules are very common and the vast majority are benign; however, fine-needle aspiration biopsy may be required based on ultrasound features for malignancy risk assessment.

Management of Graves' Disease

Endokrinoloji

Graves' disease is the most common cause of autoimmune hyperthyroidism, developing with excessive stimulation of the thyroid gland by thyroid-stimulating antibody (TRAb).

Management of Hashimoto's Thyroiditis

Endokrinoloji

Hashimoto's thyroiditis is the most common cause of hypothyroidism, due to autoimmune destruction of the thyroid gland with anti-TPO and anti-thyroglobulin antibodies.

Primary Adrenal Insufficiency (Addison's Disease)

Endokrinoloji

Addison's disease is a potentially life-threatening endocrine disorder presenting with cortisol and aldosterone deficiency due to autoimmune destruction of the adrenal glands.

Cushing Syndrome Diagnostic Workup

Endokrinoloji

Cushing syndrome is an endocrine disorder presenting with central obesity, striae, hypertension, and metabolic disturbances due to chronic glucocorticoid excess; its diagnosis is challenging.

Pheochromocytoma and Paraganglioma

Endokrinoloji

Pheochromocytomas and paragangliomas are rare tumors that secrete excess catecholamines, causing paroxysmal hypertension, headache, sweating, and palpitations.

Primary Hyperaldosteronism (Conn Syndrome)

Endokrinoloji

Primary hyperaldosteronism is a treatable cause of resistant hypertension and hypokalemia caused by excessive aldosterone secretion from the adrenal gland.

Comprehensive Evaluation of Hypopituitarism

Endokrinoloji

Hypopituitarism is a deficiency of pituitary hormone production that leads to multiple endocrine organ failures and requires lifelong hormone replacement.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.